MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity
CONCLUSION: Evaluating breast cancer response on MRI using %VR after pre-operative SABR treatment can help identify patients benefiting the most from neoadjuvant radiation treatment of their ER/PR+ HER2- tumors, a group in which pCR to neoadjuvant therapy is rare.PMID:34384695 | DOI:10.1016/j.clbc.2021.06.016
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: R Jared Weinfurtner Natarajan Raghunand Olya Stringfield Mahmoud Abdalah Bethany L Niell Dana Ataya Angela Williams Blaise Mooney Marilin Rosa Marie C Lee Nazanin Khakpour Christine Laronga Brian Czerniecki Roberto Diaz Kamran Ahmed Iman Washington Michae Source Type: research
More News: Breast Cancer | Breast Lumpectomy | Cancer | Cancer & Oncology | HER2 | Lumpectomy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Pathology | Study | Women